CD274 and neoplasm: Several predictive biomarkers, including PD-L1, tumor mutation burden (TMB), and tumor-infiltrating lymphocytes (TILs), have been proposed to predict the efficacy of IO, but their roles remain inconclusive [3, 4, 8, 32].